Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke.TOKYO, November 7 /PRNewswire/ -- - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation atrial fibrillation
Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. are Undertreated With Antiplatelet an·ti·plate·let
Acting against or destroying blood platelets.
directed against or destructive to blood platelets; inhibiting platelet function. and Anticoagulant Therapies
A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their risk for cardiovascular death, heart attack and stroke, according to according to
1. As stated or indicated by; on the authority of: according to historians.
2. In keeping with: according to instructions.
3. new findings from the large, international REACH registry published today in the American Heart Journal.(1) The findings also showed that standard treatments including anticoagulant and antiplatelet therapies are underused in AF patients.
The new findings from the REACH (REduction of Atherothrombosis for Continued Health) registry showed that AF was present in approximately 12% of patients who had atherothrombotic disease, which includes coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. (CAD), peripheral artery disease (PAD), and cerebrovascular disease cerebrovascular disease Neurology Any vascular disease affecting cerebral arteries–eg ASHD, diabetic vasculopathy, HTN, which may cause a CVA or TIA with neurologic sequelae–speech, vision, movement of variable duration. (CVD CVD Cardiovascular disease, see there ). The findings also showed that, among patients with or at risk for atherothrombotic disease, the risk for death and non-fatal cardiovascular outcomes was greater for AF vs. non-AF patients, including more than twice as high for CV death (3.2% vs 1.4%; p<0.0001), 87% higher for death from all causes (4.3% vs. 2.3%, p<0.0001), 50% higher for non-fatal stroke (2.4% vs 1.6%, p<0.0001), and nearly 50% higher for the combined endpoint of CV death/heart attack/stroke and/or hospitalization for atherothrombotic events (17.9% vs 12.1%, p<0.0001). Despite these higher risks in AF patients, only a little more than half received anticoagulant therapy, only 60 percent received antiplatelet therapy antiplatelet therapy Hematology Any therapy that inhibits platelet adhesion and/or aggregation, both of which ↑ complications of ASHD. See Aspirin, Thrombolytic therapy. , and less than one in five received both.
"We've known that AF is a major risk factor for ischemic stroke, but its prevalence and impact in the broader population of patients with atherothrombosis was previously unclear," said, lead author Shinya Goto, MD, PhD, FACC FACC Fellow, American College of Cardiology , Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan. "Our findings help fill that gap, and show across all atherothrombotic disease categories, AF consistently increases the risk of death and non-fatal CV outcomes. For example, the combined endpoint of CV death, heart attack and stroke and/or hospitalization for atherothrombotic events was higher in AF patients no matter what form of atherothrombotic disease they initially had, and was highest in patients initially recruited with PAD. Further, our analysis underscores the need to determine the optimal management of AF patients with or at risk for atherothrombosis."
About the New REACH Analysis
The REACH registry is a large, contemporary, representative and geographically diverse cohort of stable outpatients with or at high risk of atherothrombosis.2,(3),(4) A total of 68,236 patients with either established atherothrombotic disease (CAD, PAD, or CVD, n=55,814) or at least three risk factors for atherothrombosis (n=12,422) were enrolled from 5,587 physician practices in 44 countries (in Europe, North and South America and Asia) in 2003-2004.
For this new analysis, the investigators identified REACH registry patients with or without AF, then compared those two groups in terms of risk factors, drug usage and one-year cardiovascular (CV) outcomes (CV death, heart attack and stroke).
AF status and one-year follow-up data were available for 63,589 patients. The prevalence of AF was 12.5%, 13.7%, 11.5%, and 6.2% among CAD, CVD, PAD, and risk factor-only patients, respectively; and 11.7% in patients with symptomatic atherothrombotic disease (CAD, CVD, or PAD together as one group). These prevalence rates are substantially higher than the estimated prevalence in the general population aged 40 years or more (2.3%) or 65 years or more (5.9%).(5)
Of the total 6,814 AF patients, 6.7% experienced CV death, non-fatal MI or non-fatal stroke within a year. Among the findings, the investigators showed that, after statistically adjusting for differences including age, sex, smoking, hypertension, diabetes, and hypercholesterolemia Hypercholesterolemia Definition
Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal.
Cholesterol circulates in the blood stream. It is an essential molecule for the human body. , the risks for death and non-fatal CV outcomes were worse in AF vs. non-AF patients:
- CV death 129% greater (3.2% vs 1.4%; p<0.0001) - All-cause death 87% greater (4.3 vs 2.3, p<0.0001) - Non-fatal stroke 50% greater (2.4% vs 1.6%, p<0.0001) - The combined endpoint of CV death/heart attack/stroke and/or hospitalization for atherothrombotic event 48% greater (17.9% vs 12.1%, respectively; p<0.0001), and highest in patients initially recruited with PAD (27.1%)
Only 58.4% of AF patients received antiplatelet agents, and only 53.1% received anticoagulant therapy. The rate of bleeding requiring hospitalization was higher in AF vs non-AF patients, respectively: 1.5% vs 0.8% (p<0.0001); the investigators speculated that this may have been due to the more frequent use of anticoagulants (53.1% vs 7.1%).
1. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863.
2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-189.
3. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151(4):786 e1-10.
4. Steg PG, Bhatt DL, Wilson PWF PWF Pacific Whale Foundation (Maui, Hawaii)
PWF Public Workstation Facility
PWF Polarimetric Whitening Filter
PWF Pro Wrestling Fan
PWF Preserved Wood Foundation
PWF Peter Westbrook Foundation
PWF Personnel Working File
PWF Power Weight Filter , D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155(5):469-73.
CONTACT: For Further Information, please contact: Nick James, Chandler Chicco Agency, +44(0)7776-258-990, firstname.lastname@example.org; Dr. Deepak Bhatt, On Behalf of the REACH STEERING COMMITTEE, +1-857-203-6840/6841; Dr. Shinya Goto, Tokai University, +81-463-58-1211